
Sagimet Biosciences Inc. - Series A: updates and filings
Price
$9.08
November 20, 2026Market cap $566M
What Ploutos Investor adds for Sagimet Biosciences Inc. - Series A
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 22, 2026Regulation FD disclosureForm8-K
- Oct 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 1, 2026Material agreement enteredForm8-K
- Sep 30, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Other material eventsForm8-K
- Aug 11, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 21, 2026Regulation FD disclosureForm8-K
- Jun 12, 2026Officer or director change, shareholder voteForm8-K
- Jun 3, 2026Officer or director changeForm8-K
- May 12, 2026Results of operationsForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 28, 2026Material agreement enteredForm8-K
- Apr 27, 2026Regulation FD disclosureForm8-K
- Apr 27, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Apr 21, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 21, 2026Annual meeting proxy statementFormDEF 14A
- Apr 21, 2026Officer or director change, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 22, 2026 | 8-K | Regulation FD disclosure | Document |
| Oct 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 1, 2026 | 8-K | Material agreement entered | Document |
| Sep 30, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | 8-K | Other material events | Document |
| Aug 11, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 21, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 12, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Jun 3, 2026 | 8-K | Officer or director change | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 28, 2026 | 8-K | Material agreement entered | Document |
| Apr 27, 2026 | 8-K | Regulation FD disclosure | Document |
| Apr 27, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Apr 21, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 21, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 21, 2026 | 8-K | Officer or director change, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 8, 2007.
The full analysis
What do Sagimet Biosciences Inc. - Series A's filings show?
The filings are where every one of Sagimet Biosciences Inc. - Series A's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.